SAN DIEGO, Oct. 30, 2018 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced financial results for the quarter ended September 30, 2018.

Third Quarter 2018 Highlights

• Revenue increased 9.8% to $271.3 million, or 10.2% on a constant currency basis;
• GAAP operating profit margin of 6.6%; Non-GAAP operating profit margin of 15.6%;
• GAAP diluted earnings per share of $0.30; Non-GAAP diluted earnings per share of $0.56; and
• Company updates full-year 2018 guidance.

“Our third quarter results reflect accelerated year-over-year revenue growth of nearly 10%, supported by strong performances in both spinal hardware and surgical support business lines with overall U.S. case volumes up more than 7%,” said Gregory T. Lucier, chairman and chief executive officer of NuVasive. “With the sense the overall U.S. spine market is trending healthier, we made strategic investments this quarter on the heels of this momentum in key R&D initiatives, additions to our commercial sales force and infrastructure upgrades to improve set fulfillment—all to support a strong start to 2019 and beyond.” 

The Company’s financial results reflect continued improvement of its in-sourcing efforts at the West Carrollton, Ohiomanufacturing facility, and the Company reiterated expectations that the facility will drive an additional 130 to 150 basis points in operating margins in 2019.

Lucier commented, “We made solid progress with our in-source manufacturing initiatives by bringing in additional SKUs during the third quarter with throughput ramping to higher volumes. This strategic investment is on track and will become a business advantage, both to drive a competitive cost position and to control the quality required to produce evermore complex implants.”

NuVasive also recently made several key technology introductions and partnership announcements, including the unveiling of the NuVasive Pulse™ surgical automation platform, Spine Precision Partnership with Siemens Healthineers and signing of a strategic partnership with Biedermann Technologies to further enhance NuVasive’s best-in-class complex spine deformity technologies. The Company also launched several new products to further reinvigorate its Biologics business line, which continues to recover at a faster-than-expected pace. The Company now anticipates its Biologic business will return to growth in the fourth quarter 2018.

A full reconciliation of GAAP to non-GAAP measures can be found in the tables of this news release.

Third Quarter 2018 Results

NuVasive reported third quarter 2018 total revenue of $271.3 million, a 9.8% increase compared to $247.1 million for the third quarter 2017. On a constant currency basis, third quarter 2018 total revenue increased 10.2% compared to the same period last year.

For the third quarter 2018, GAAP and non-GAAP gross profit was $197.1 million and $197.4 million, respectively, while GAAP and non-GAAP gross margin was 72.7% and 72.8%, respectively. These results compared to GAAP and non-GAAP gross profit of $181.5 million and $181.7 million, respectively, and both GAAP and non-GAAP gross margin of 73.5% for the third quarter 2017. Total GAAP and non-GAAP operating expenses were $179.2 million and $155.1 million, respectively, for the third quarter of 2018. These results compared to GAAP and non-GAAP operating expenses of $151.1 million and $138.4 million, respectively, for the third quarter 2017.

NuVasive reported GAAP net income of $15.9 million, or $0.30 per diluted share, for the third quarter 2018 compared to GAAP net income of $33.5 million, or $0.64 per diluted share, for the third quarter 2017. On a non-GAAP basis, NuVasive reported net income of $29.5 million, or $0.56 per diluted share, for the third quarter 2018 compared to net income of $26.6 million, or $0.51 per diluted share, for the third quarter 2017.

Annual Financial Guidance for 2018

The Company updated its full-year 2018 financial guidance by increasing its revenue guidance by $5 million to reflect a new range of $1,100 million to $1,110 million and reducing its non-GAAP operating margin guidance range to 15.0% – 15.5% as a result of accelerated investments in infrastructure and commercial sales force in anticipation of the overall spine market growth trending up to more historical averages.

• Full-year 2018 revenue in the range of $1,105 million to $1,110 million reflecting reported growth of 7.6% to 8.1%, and growth in the range of 5.7% to 6.2%, exclusive of the SafePassage acquisition;
• Non-GAAP diluted earnings per share in a range of $2.15 to $2.23 compared with the prior expectation of $2.37 to $2.40;
• Non-GAAP operating profit margin in the range of 15.0% to 15.5%, compared with the prior expectation of 16.7%;
• Adjusted EBITDA margin in the range of 24.4% to 24.9%, compared with the prior expectation of 25.9%;
• Non-GAAP effective tax expense rate of approximately 21%;
• The Company expects currency to have a positive impact on revenue in 2018 of approximately $2 million compared with the prior expectation of $3 million; and
• The Company expects to drive an adjusted EBITDA of approximately $269 million to $276 million, compared with the prior expectation of approximately $283 million to $293 million.

The above guidance assumes a full-year benefit of U.S. tax reform, suspension of the medical device tax and the SafePassage acquisition.

Supplementary Financial Information

For additional financial detail, please visit the Investor Relations section of the Company’s website at www.nuvasive.comto access Supplementary Financial Information.

October 29, 2018

LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (previously Orthofix International N.V.) (NASDAQ:OFIX) today reported its financial results for the third quarter ended September 30, 2018. Net sales were $111.7 million, net loss per share from continuing operations was $0.07 and adjusted earnings per share from continuing operations was $0.43.

“In addition to solid financial performance on both the top line and adjusted EBITDA in the third quarter, we made significant operational progress in the alignment of our Bone Growth Therapy, Spinal Implants and Biologics segments into Orthofix Spine,” said Brad Mason, Orthofix President and Chief Executive Officer. “We believe that our market-leading technologies in osteogenesis stimulation and stem cell allografts, together with the M6 cervical disc, once it is approved by the U.S. Food and Drug Administration, will uniquely position us in the spine market overall and particularly in the cervical spine segment. We also believe this combination of spine products in conjunction with our historical strength in Orthofix Extremities provides the platforms for us to drive accelerating growth as we move into 2019 and for the foreseeable future.”

Financial Results Overview

The following table provides net sales by reporting segments:

Gross margin increased 100 basis points compared to the prior year period primarily driven by costs savings from our 2017 U.S. restructuring initiative and continued improvement related to inventory management initiatives. Non-GAAP net margin, an internal metric that the Company defines as gross profit less sales and marketing expenses, was $37.8 million compared to $34.0 million in the prior year period. As a percentage of net sales, non-GAAP net margin increased to 33.8% as compared to 32.3% in the prior year period, primarily due to the improvement in gross margin and improvements in commission rates.

GAAP net loss from continuing operations was ($1.2) million, or ($0.07) per share, compared to net income of $3.3 million, or $0.18 per share in the prior year period. This decrease was primarily driven by changes in the fair value of contingent consideration associated with the acquisition of Spinal Kinetics and an unrealized loss on investment securities recognized during the third quarter of 2018. Adjusted net income from continuing operations was $8.2 million, or $0.43 per share, compared to adjusted net income of $7.7 million, or $0.42 per share in the prior year period. Excluding the impact of the Spinal Kinetics operating loss in the period, adjusted net income was $9.5 million, or $0.50 per share, a 19.0% increase over prior year.

EBITDA was $3.6 million, compared to $14.5 million in the prior year period. Adjusted EBITDA was $21.4 million, or 19.2% of net sales, for the third quarter, compared to $21.1 million, or 20.1% of net sales, in the prior year period.

Liquidity

As of September 30, 2018, cash, cash equivalents, and restricted cash totaled $56.2 million compared to $81.2 million as of December 31, 2017. As of September 30, 2018, the Company had no outstanding indebtedness and borrowing capacity of $125 million under its existing credit facility. Cash flow from operations was $28.8 million, an increase of $19.7 million, and free cash flow was $18.1 million, an increase of $22.3 million when compared to the same prior year period.

2018 Updated Outlook

For the year ending December 31, 2018, the Company expects the following results, assuming exchange rates are the same as those currently prevailing.

Conference Call

Orthofix will host a conference call today at 4:30 PM Eastern time to discuss the Company’s financial results for the third quarter of 2018. Interested parties may access the conference call by dialing (844) 809-1992 in the U.S. and (612) 979-9886 outside the U.S., and referencing the conference ID 6295495. A replay of the call will be available for two weeks by dialing (855) 859-2056 in the U.S. and (404) 537-3406 outside the U.S., and entering the conference ID 6295495. A webcast of the conference call may be accessed by going to the Company’s website at www.orthofix.com, by clicking on the Investors link and then the Events and Presentations page.

About Orthofix

Orthofix Medical Inc. is a global medical device company focused on musculoskeletal products and therapies. The Company’s mission is to improve patients’ lives by providing superior reconstruction and regenerative musculoskeletal solutions to physicians worldwide. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedic extremities products are distributed in over seventy countries via the Company’s sales representatives and distributors. For more information, please visit www.orthofix.com.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (“the Exchange Act”), and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” or “continue” or other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict. Therefore, our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to further update any such statement, or the risk factors described in Part I, Item 1A under the heading Risk Factors in our Form 10-K for the year ended December 31, 2017 and other SEC filings, to reflect new information, the occurrence of future events or circumstances or otherwise.

READ THE REST HERE

WARSAW, Ind., Oct. 26, 2018 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2018.  The Company reported third quarter net sales of $1.837 billion, an increase of 1.3% over the prior year period, and an increase of 2.3% on a constant currency basis.  Diluted earnings per share for the third quarter were $0.79, an increase of 65% over the prior year period.  Third quarter adjusted diluted earnings per share were $1.63, a decrease of 5% from the prior year period.

“We are pleased with our third quarter accomplishments, which reflect our sustained progress in a number of areas.  Although our sales results clearly benefited from less challenging sales comparisons, as well as the timing of certain tenders and capital sales, our organic growth continued to signal that we are turning the business around consistent with our expectations,” said Bryan Hanson, President and CEO of Zimmer Biomet.  “Looking to the balance of the year, we will continue to focus on priorities to improve the consistency of our results and drive sustained value creation.  These include important new innovations that are expanding our comprehensive portfolio, advancing standards of care and creating new opportunities for our salesforce to deliver growth.”

Net earnings for the third quarter were $162.2 million, and $334.6 million on an adjusted basis.  Operating cash flow for the third quarter was $484.1 million.  Free cash flow in the quarter was $345.0 million.

In the quarter, the Company paid $48.8 million in dividends and declared a third quarter dividend of $0.24 per share.

Guidance

The Company made minor updates to its full-year 2018 guidance.  The only factors changing are the expected impact of foreign currency and the expected adjusted effective tax rate.  All other prior guidance for 2018 remains unchanged.

• The Company now expects the positive impact of foreign currency translation to be slightly below the low end of the previous range of 100 to 150 basis points, due to the strengthening of the dollar over the last several months.
• The Company now expects the adjusted effective tax rate for the full year to be slightly below the low end of the previous range of 18.5% to 19.5%⁽¹⁾.

Conference Call

The Company will conduct its third quarter 2018 investor conference call today, October 26, 2018, at 8:30 a.m. Eastern Time.  The audio webcast can be accessed via Zimmer Biomet’s Investor Relations website at http://investor.zimmerbiomet.com.  It will be archived for replay following the conference call.

Sales Tables
The following sales tables provide results by geography and product category, as well as the percentage change compared to the prior year quarter and nine months, on both a reported basis and a constant currency basis.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Website Information

We routinely post important information for investors on our website, www.zimmerbiomet.com, in the “Investor Relations” section.  We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.  Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts.  The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

Reclassifications

Beginning in the second quarter 2018, in our consolidated statements of earnings we have reclassified expenses that were previously recognized in a financial statement line item labeled, “Acquisition, quality remediation and other” to the financial statement line items of “Research and development”, “Selling, general and administrative”, “Goodwill and intangible asset impairment”, “Acquisition, integration and related”, and “Quality remediation”.  Prior periods have been reclassified to conform to the current year presentation.

Note on Non-GAAP Financial Measures

This press release includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”).  These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.

Sales change information for the three and nine-month periods ended September 30, 2018 are presented on a GAAP (reported) basis and on a constant currency basis.  Constant currency percentage changes exclude the effects of foreign currency exchange rates.  They are calculated by translating current and prior-period sales at the same predetermined exchange rate.  The translated results are then used to determine year-over-year percentage increases or decreases.

Net earnings and diluted earnings per share for the three and nine-month periods ended September 30, 2018 are presented on a GAAP (reported) basis and on an adjusted basis.  Adjusted earnings and adjusted diluted earnings per share exclude the effects of inventory step-up; certain inventory and manufacturing-related charges, including charges to discontinue certain product lines; intangible asset amortization; goodwill and intangible asset impairment; acquisition, integration and related expenses; quality remediation expenses; certain litigation gains and charges; other charges; any related effects on our income tax provision associated with these items; and other certain tax adjustments.

Free cash flow is an additional non-GAAP measure that is presented in this press release. Free cash flow is computed by deducting additions to instruments and other property, plant and equipment from net cash provided by operating activities.

Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this press release. This press release also contains supplemental reconciliations of additional non-GAAP financial measures that the Company presents in other contexts. These additional non-GAAP financial measures are computed from the most directly comparable GAAP financial measure as indicated in the applicable reconciliation.

Management uses non-GAAP financial measures internally to evaluate the performance of the business.  Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the Company.  Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income but that do not impact the fundamentals of our operations.  The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures.  In addition, constant currency sales changes, adjusted operating profit, adjusted diluted earnings per share and free cash flow are used as performance metrics in our incentive compensation programs.

Forward-Looking Non-GAAP Financial Measures

This press release also includes the forward-looking non-GAAP financial measure of adjusted effective tax rate for the year ending December 31, 2018.  We calculate forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures.  For instance, we exclude the impact of certain potential charges or gains connected to quality remediation efforts and certain legal and tax matters.  We have not provided a quantitative reconciliation of this forward-looking non-GAAP financial measure to the most directly comparable forward-looking GAAP financial measure because the excluded items are not available on a prospective basis without unreasonable efforts.  It is probable that this forward-looking non-GAAP financial measure may be materially different from the corresponding GAAP financial measure.

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding sales and earnings guidance and any statements about our expectations, plans, strategies or prospects.   We generally use the words “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “assumes,” “guides,” “targets,” “forecasts,” “sees,” “seeks,” “should,” “could,” “intends” and similar expressions to identify forward-looking statements.   All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements.   Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially.  These risks, uncertainties and changes in circumstances include, but are not limited to:  our chief executive officer transition, including disruptions and uncertainties related thereto, the potential impact on our business and future strategic direction resulting from our transition to a new chief executive officer, and our ability to recruit and retain other key members of senior management; the possibility that the anticipated synergies and other benefits from mergers and acquisitions will not be realized, or will not be realized within the expected time periods; the risks and uncertainties related to our ability to successfully integrate the operations, products, employees and distributors of acquired companies; the effect of the potential disruption of management’s attention from ongoing business operations due to integration matters related to mergers and acquisitions; the effect of mergers and acquisitions on our relationships with customers, vendors and lenders and on our operating results and businesses generally; compliance with the Deferred Prosecution Agreement entered into in January 2017; the success of our quality and operational excellence initiatives, including ongoing quality remediation efforts at our Warsaw North Campus facility; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration (FDA) and foreign government regulators, such as more stringent requirements for regulatory clearance of products; the ability to remediate matters identified in any inspectional observations or warning letters issued by the FDA, while continuing to satisfy the demand for our products; the outcome of government investigations; competition; pricing pressures; changes in customer demand for our products and services caused by demographic changes or other factors; the impact of healthcare reform measures; reductions in reimbursement levels by third-party payors and cost containment efforts of healthcare purchasing organizations; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; control of costs and expenses; the ability to obtain and maintain adequate intellectual property protection; the ability to form and implement alliances; changes in tax obligations arising from tax reform measures, including European Union rules on state aid, or examinations by tax authorities; product liability and intellectual property litigation losses; the ability to retain the independent agents and distributors who market our products; dependence on a limited number of suppliers for key raw materials and outsourced activities; changes in general industry and market conditions, including domestic and international growth rates; changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; and the impact of the ongoing financial and political uncertainty on countries in the Euro zone on the ability to collect accounts receivable in affected countries.  For a further list and description of such risks and uncertainties, see our reports filed with the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2017.  Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.zimmerbiomet.com or on request from us.  Forward-looking statements speak only as of the date they are made, and we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  Readers of this release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this release.

READ THE REST HERE

October 23, 2018

October 24, 2018

SAN FRANCISCO, October 24, 2018 /PRNewswire/ —

The global ambulatory surgery center market is subject to witness a substantial growth over the forecast period due to the growing geriatric population, rising occurrence of chronic diseases, surging in healthcare costs, and recent technological advancements in the healthcare sector. However, absence of expertise and increase in number of reimbursement issues are restraining the market growth, in the recent years. Yet, recent technological advancements such as the development of big multi-service ambulatory care centers are expected to fuel the growth of ambulatory surgery center industry in upcoming years. Growing healthcare expenditure by developed economies across the globe are driving demand for the ambulatory surgery center, in the recent years. Ambulatory surgical center helps to solve several issues like treatment delay, absence of healthcare facilities, and higher cost. Lack of proper healthcare facilities particularly in rural areas of developing economies across the globe are anticipated to boost demand for ambulatory surgery center, thus providing lucrative growth opportunities for ambulatory care providers in near future. Increase in number of initiatives undertaken by local governments in collaboration with private bodies in both developing and developed economies to provide outpatient medical services in remote location where there is shortage of medical facilities, are expected to fuel the growth of ambulatory surgery center industry over the forecast period. Advent of improved pain operating methods in ambulatory surgery centers with the help of recent technological advancement that includes advanced surgical methodologies, anesthesia and enhanced drugs, are spurring market growth.

Other factors responsible for sustained the growth of ambulatory surgery center market are increase in the number of surgeries performed each year, substantial investment by private & public bodies, and reduced cost of clinical surgeries. Ambulatory care is termed as the process where surgical procedure is performed on a patient outside of the hospital premises or at remote locations. Ambulatory surgery center typically consists of all necessary medical facilities and surgical equipment that is required during operational procedures. Ambulatory surgery centers are well equipped with surgical equipment such as scalpels, scissors, saws, towel clamps, vascular clamps and more. Ambulatory surgery centers also contains life-supporting systems that are well organized to offer cost-effective medical services during critical situations. Limited healthcare facilities in rural area and growing patient pool are some of the critical factors driving the growth of ambulatory surgery centers industry in the last few years. Presence of ambulatory surgery centers in such scenarios aids in easing up the pressure on present medical facilities in the region. Lower cost associated with ambulatory surgery centers in comparison with the hospitals and nursing homes are predicted to amplify market expansion during the forecast period. The ambulatory surgery center industry is broadly divided into two categories such as hospital-based ambulatory surgery centers and freestanding ambulatory surgery centers. Hospital-based ambulatory surgery center is considered as one of the fastest growing segment in the ambulatory surgery center market with substantial revenue generation in the last couple of years. Ambulatory surgery center is capable of performing various surgical treatments such as laceration treatment, bone fracture treatment, emergency care service, and trauma or accident treatment.

The ambulatory surgery center industry is divided by region as North America, Europe, Asia-Pacific, Latin America and Africa. North America has shown major growth in recent years owing to the rise in the adoption of latest technologies in medicine & pharmaceutical sector and existence of well-established healthcare infrastructure. Other factors driving North America market include rise in the number of advanced diagnostic methodologies and increase in prevalence of orthopedics, ophthalmology, gastroenterology, plastic surgery, and chronic pain. Asia-Pacific region is predicted to hold major market share in the ambulatory surgery center industry with massive growth in forecast period. Countries such as India, China and Singapore are leading the Asia-Pacific market with increase in the occurrence of angle closure glaucoma & myopia, longer in life expectancy, recent infrastructural activities such as development of emergency care centers outside conventional hospital settings, and significant investment by leading industry players considering potential growth opportunities in the region. The key players in the ambulatory surgery center industry are Surgery Partners, Inc., Envision Healthcare Co., IntegraMed America Incorporations, Symbion Incorporations, Terveystalo Co., NueHealth LLC, Aspen Healthcare Ltd., and Medical Facilities Co.

Access 115 page research report with TOC on “Ambulatory Surgery Center Market“ available with Radiant Insights, Inc. @ https://www.radiantinsights.com/research/global-ambulatory-surgery-center-industry-2018

In this report, the global Ambulatory Surgery Center market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

• Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Ambulatory Surgery Center in these regions, from 2013 to 2025 (forecast), covering

• North America
• Europe
• China
• Japan
• Southeast Asia
• India

• Global Ambulatory Surgery Center market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

• AmSurg
• THC
• HCA Healthcare
• Mednax
• Team Health
• Surgical Care Affiliates
• QHC
• Surgery Partners
• Medical Facilities
• NOVENA
• Community
• Terveystalo Healthcare
• SurgCenter Development
• Elmhurst
• Healthway Medical
• SCH
• Eifelhoehen-Klinik

• On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Single-specialty Centers
• Multi-specialty Centers

• On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including

• Gastroenterology
• Ophthalmology
• Pain Management
• Orthopedics
• Others

Browse reports of similar category available with Radiant Insights, Inc.:

• Surgical Scalpel Blade Market

• Automatic CPR Devices Market 

• Enteroscopes Market

• Internal Trauma Fixation Devices Market

About Radiant Insights, Inc.:

At Radiant Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact:
Michelle Thoras.
Corporate Sales Specialist
Radiant Insights, Inc.
Phone: +1-415-349-0054
Toll Free: 1-888-928-9744
Email: sales@radiantinsights.com

Web: https://www.radiantinsights.com

SOURCE Radiant Insights, Inc.

Seattle, Oct. 22, 2018 (GLOBE NEWSWIRE) — According to Coherent Market Insights, the global collagen meniscus implant market was valued at US$ 358.8 million in 2017 and is projected to exhibit a CAGR of 5.4% over the forecast period (2018–2026).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/collagen-meniscus-implant-market-2229

Key Trends and Analysis of the Collagen Meniscus Implant Market:

The collagen meniscal implant (CMI) (previously marketed as Menaflex) is derived from bovine collagen and is used to treat acute or chronic advanced meniscal loss or damage with the intent of relieving symptoms and preventing joint degeneration. According to the National Institute of Health Research 2017 report, meniscal replacement with CMI is indicated for patients with advanced loss of or damage to meniscal tissue that cannot be repaired. Moreover, the amount of damaged tissue must be over 25% of the total meniscus area and should extend at least into the red-white zone.

Increasing number of sports injuries and rising geriatric population are major factors that are expected to drive growth of the collagen meniscus implant market over the forecast period. According to the Journal of Athletic Training 2012 study, the risk of tearing a meniscus in the age group over 40 years was reported to be four times larger in comparison to age group below 20 years.

Manufacturers in the collagen meniscus implant market focus on developing new products and strategic mergers & acquisitions, in order to gain significant market share. For instance, in 2016, Stryker acquired New Jersey-based Ivy Sports Medicine, a company that develops minimally invasive meniscal repair solutions, for an undisclosed amount.

Request Sample Copy of this Report

Key Market Takeaways:

• The global collagen meniscus implant market is expected to exhibit a CAGR of 5.4% during the forecast period (2018–2026), owing to increasing incidences of sports-related knee injuries
• North America collagen meniscus implant market is expected to generate significant revenue share during the forecast period, owing to increasing number of meniscus surgeries being performed in the region. As per the National Center for Health Statistics 2017 report, meniscus surgery is the most frequent surgical procedure performed by orthopedic surgeons in the U.S., with over 50% of the procedures performed in patients 45 years of age or older.
• Key players operating in the global collagen meniscus implant market include Active Implants, Orthonika, RTI Surgical, Stryker Corporation, and Zimmer Biomet

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave. 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

HOLLAND, Mich., Oct. 22, 2018 /PRNewswire/ — Shoulder Innovations, an emerging leader in the development of shoulder replacement systems, announced today it has closed a $2.5 million round of Series A equity funding led by Ann Arbor-based Michigan Angel Fund, Grand Rapids-based Wakestream Ventures, Genesis Innovation Group, cultivate(MD) and other equity holders.

“It is impressive that the team at Shoulder Innovations has developed truly cutting-edge and disruptive products in the orthopedic space, and they have done so in a capital efficient manner, which we love to see,” said Skip Simms, Managing Director Michigan Angel Fund.

More than 100,000 patients receive shoulder replacement surgery each year, with demand increasing ten percent annually.  An increasing prevalence of shoulder arthritis, combined with the aging Baby Boomer population is driving the growth of the global shoulder arthroplasty market, which is valued at more than $1 billion and is expected to double by 2023.

Shoulder Innovations is positioned advantageously within the market with a straightforward surgical technique, highly stable implant, and streamlined instrumentation, which provides opportunity for improved operating room performance.

The $2.5 million investment will be used to fuel new product development, and to acquire inventory and assets to accelerate growth of its current Inset platform technology, which serves as a foundational platform on which many future products and systems are in development.  The long-term vision of Shoulder Innovations is to offer a complete leading technology shoulder arthroplasty product line.

“Shoulder Innovations has made excellent progress in both its commercial growth and its innovative development initiatives over the past several quarters.  We are extremely excited by the continued support and encouragement from our investment partners to continue this work which will significantly impact the lives of many,” said Rob Ball, Executive Chairman of Shoulder Innovations.

About Shoulder Innovations:
Shoulder Innovations, LLC is a medical device development company which designs and commercializes innovative products which demonstrate the potential for improved patient care and reduced overall cost to the healthcare system.

Leveraging its breakthrough, patented, inset glenoid design, Shoulder Innovations is commercializing a shoulder replacement implant system focused on improving outcomes related to the greatest cause of shoulder replacement failure: glenoid loosening.

The inset technology has been shown in testing to significantly reduce glenoid implant micro-motion and simplifies surgical the surgical technique, potentially reducing complications or increase implant longevity. Shoulder Innovations is based in Holland, Mich.

Learn more about Shoulder Innovations and its Total Shoulder Replacement System at shoulderinnovations.com.

SOURCE Shoulder Innovations

Related Links

http://shoulderinnovations.com